Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mildly Impaired Renal Function Clear all
Completed Phase 1 Interventional

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

NCT00585143
View directory record Official record
Conditions
Dyslipidemia, Renal Insufficiency
Interventions
ABT-335, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Gainesville, Florida • Miami, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

CellCept in p-ANCA Vasculitis

NCT00405860
View directory record Official record
Conditions
MPO-ANCA Vasculitis, Microscopic Polyangiitis
Interventions
CellCept (mycophenolate mofetil)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Venglustat in Patients With Renal Impairment

NCT03687554
View directory record Official record
Conditions
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
129
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)

NCT01084278
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Sep 28, 2026, 8:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579
View directory record Official record
Conditions
Renal Impairment
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

NCT02199379
View directory record Official record
Conditions
Renal Impairment, Disease Severity
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

NCT01708889
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Chronic Hepatitis C Virus Infection
Interventions
BMS-914143 (Peginterferon Lambda-1a)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

NCT03087942
View directory record Official record
Conditions
Renal Insufficiency
Interventions
QAW039, QAW39A, QAW39A2107
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

NCT00567047
View directory record Official record
Conditions
Type-2 Diabetes
Interventions
vildagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

NCT00750620
View directory record Official record
Conditions
Renal Impairment
Interventions
YM178
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 28, 2026, 8:03 AM EDT
Terminated Phase 1 Interventional

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

NCT02679131
View directory record Official record
Conditions
Relapsed/Refractory Solid Tumors/Hematological Malignancies
Interventions
Belinostat
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Whittier, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 3 Interventional Results available

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

NCT01818596
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

NCT01763190
View directory record Official record
Conditions
Renal Impairment
Interventions
SAR302503
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Results available

Mild, Moderate and Severe Renal Impairment Study

NCT02219516
View directory record Official record
Conditions
Gout
Interventions
RDEA3170
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 28, 2026, 8:03 AM EDT
Recruiting Not applicable Interventional

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

NCT05655325
View directory record Official record
Conditions
Mild Cognitive Impairment, Chronic Kidney Diseases
Interventions
Home-based walking exercise, Attention control
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

NCT07154901
View directory record Official record
Conditions
Renal Impairment
Interventions
Opemalirsen (AZD2373)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment

NCT02653014
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Evergreen Park, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 4 Interventional Results available

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

NCT00369382
View directory record Official record
Conditions
Graft Rejection, Kidney Failure
Interventions
cyclosporine or tacrolimus, sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 28, 2026, 8:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

NCT04678505
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3402
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

NCT00543075
View directory record Official record
Conditions
Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function
Interventions
Genasense (oblimersen, G3139)
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Weeks and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 28, 2026, 8:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.

NCT03890770
View directory record Official record
Conditions
Renal Impairment, Healthy Volunteer
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 28, 2026, 8:03 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 28, 2026, 8:03 AM EDT